Top U.S. drugmaker by market value Pfizer (PFE) said it will file with the FDA for early approval of new breast cancer drug palbociclib. The filing will process as the drug finishes clinical trials. Pfizer completed a mid-stage trial and said it will base the filing on those results, which it said showed a strong, progression-free survival rate. The cancer drug is expected to generate annual sales of $3 bil by '20. Pfizer shares rose 0.2% to 29.12.